Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis Authors: Gonçalo Boleto, Anne Cauvet, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Lih-Yun Hsu, James T. Rosenbaum, Richard A. Miller, Yannick Allanore Published: 2025 ABSTRACT BackgroundInterleukin-2-inducible T cell kinase (ITK) is a tyrosine kinase involved in T cell activation, differentiation, and receptor signaling. Soquelitinib (SQL) is a selective, covalent inhibitor of ITK. The abnormal activation of T cells plays a key role in the early inflammatory stages of systemic sclerosis (SSc). In the study reported here, we investigated the efficacy of SQL in two mouse models of lung fibrosis, and related pulmonary arterial hypertension (PAH), mimicking lung involvement in SSc.MethodsSQL was evaluated in the bleomycin-induced lung fibrosis mouse model and the Fra-2 mouse model, characterized by interstitial lung disease (ILD) and pulmonary vascular remodeling leading to PAH.ResultsIn the bleomycin-induced lung fibrosis model, SQL significantly reduced leucocyte infiltration into the lungs and attenuated interstitial lung damage, primarily by modulating Th2 and Th17 pathways, although it did not affect collagen deposits. In the Fra-2 model, SQL improved clinical scores, reduced histological scores of interstitial lung damage and inflammatory infiltrates, and significantly downregulated Th17-dependent RORγt and STAT3 expression in lesional lungs. While SQL showed a trend toward improved lung function on imaging and modest effects on collagen deposits, it significantly reduced PAH in the Fra-2 mice, improving key cardiac hemodynamic parameters and showing trends of beneficial effects on vascular remodeling.ConclusionsOur findings highlight the potential of selective ITK inhibition with SQL as a promising therapeutic strategy for lung damage and pulmonary vascular remodeling in SSc.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13075-025-03687-5. Introduction Systemic sclerosis (SSc) is a rare, complex, and incurable autoimmune condition characterized by immune-mediated microvascular damage and progressive fibrosis of the skin and internal organs [1–3]. Among the most common complications of SSc are interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), which significantly contribute to morbidity and remain the leading causes of death in patients with SSc [4, 5]. The pathogenesis of SSc is complex and not yet fully understood, however substantial evidence suggests that aberrant activation of T cells plays a central role in the early inflammatory stages of the disease, driving chronic tissue injury and subsequent fibrosis [6–8]. SSc is typically associated with a predominant Th2 immune responses [9]. Previous studies have shown elevated levels of IL-4 and IL-13 in patients with SSc, both of which are key cytokines that drive Th2 polarization [10]. The soluble mediators, IL-4, IL-6, and IL-13 released by Th2 cells, interact with fibroblasts and are suspected to contribute to fibrosis by promoting excessive extracellular matrix (ECM) deposition [9]. Concurrently, accumulating evidence pointed to a role for Th17 cells in SSc pathogenesis, with increased levels of Th17-derived IL-17 detected in the serum and skin of patients [11, 12]. IL-17, a potent pro-inflammatory cytokine, is known to promote fibrosis through its effects on fibroblast proliferation and collagen and connective synthesis [13]. The T cell receptor (TCR) is essential for the activation and proliferation of T cells. Interleukin-2-inducible T cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a critical role in mediating TCR and Fc receptor signaling [14–18]. While ITK is expressed in both Th1 and Th2 cells, studies involving knockout or genetically modified mice have shown that ITK inactivation or deletion primarily suppresses Th2 and Th17 pathways, with minimal effects on Th1 responses [18–20]. Soquelitinib (SQL) is a selective, covalent inhibitor of ITK. In vitro studies have demonstrated that SQL preferentially suppresses Th2 cytokine production and inhibits in vivo growth of several murine tumors by promoting tumor infiltration by CD8 + T cells [21]. The predominant Th2 and Th17 polarization observed in SSc, along with the properties of SQL, make it as an appealing candidate for intervention in this immune-mediated condition. In this study, we aim to assess the efficacy of SQL in two mouse models that replicate SSc-related lung damage, including ILD and PAH. Results Soquelitinib alleviates lung fibrosis in bleomycin-lung fibrosis induced mice Four groups of mice were studied, as illustrated in Fig. 1A. All groups, except Group1 (which received phosphate buffered saline, PBS), were challenged with bleomycin administered via the oro-pharyngeal delivery on days 0 and 6. Group 2 received the vehicle diluent, while Groups 3 and 4 were treated with SQL at two different doses (30 mg/kg or 10 mg/kg) from days 7 to 21, given once daily by oral gavage. As expected, bleomycin treatment caused a significant increase in lung weight (Fig. 1B). Both doses of SQL limited this increase, reducing lung weight by 12.5% (median score [IQR]: 0.402 [0.384–0.42] vs. 0.357 [0.339–0.373]; p = 0.035) with the 30 mg/kg dose (intermediate dose) and by 14.3% (0.402 [0.384–0.42] vs. 0.72 [0.37–1.57]; p = 0.0008) with the 10 mg/kg dose (low dose). Additionally, SQL treatment at 10 mg/kg resulted in 41.7% reduction in leukocyte concentration in the BALF (107500 [91250–131250] vs. 68125 [48750–88125]; p = 0.013) as shown in Fig. 1C. Both SQL doses also reduced the Ashcroft score, which is indicative of structural lung damage [22], by 28.9% (3.5 [3.1–3.6] vs. 2.5 [2.3–2.7]; p = 0.0001) and by 24.9% (3.5 [3.1–3.6] vs. 2.7 [2.3–2.8]; p = 0.0008) for SQL 30 mg/kg and 10 mg/kg, respectively. While both doses of SQL reduced collagen deposit, the effect did not reach statistical significance (Fig. 1E). Representative hematoxylin and eosin and Masson’s trichrome staining for fibrosis are shown in Fig. 1F. Fig. 1Soquelitinib (SQL) treatment protected mice against bleomycin-induced lung fibrosis. A Experimental design and group distribution. Schematic representation of the study timeline and the experimental groups used. B Absolute lung weight measured across different groups. C SQL treatment reduced the recruitment of leukocytes into the lung, as shown by the number of infiltrating leukocytes in bronchoalveolar lavage fluid (BALF). D SQL significantly decreased the severity of lung structural damage, as assessed by modified Ashcroft scores of fibrosis. E SQL treatment resulted in a moderate, but non-significant decrease in lung fibrosis. Fibrosis scores were quantified by evaluating the Masson’s Trichrome (MT)-stained lung sections are shown. F Representative images of hematoxylin and eosin and Masson’s trichrome staining for fibrosis. Each dot in the bar graphs represents one mouse. ns, non-significant, *p<0.05; *** p<0.001 Soquelitinib (SQL) treatment protected mice against bleomycin-induced lung fibrosis. A Experimental design and group distribution. Schematic representation of the study timeline and the experimental groups used. B Absolute lung weight measured across different groups. C SQL treatment reduced the recruitment of leukocytes into the lung, as shown by the number of infiltrating leukocytes in bronchoalveolar lavage fluid (BALF). D SQL significantly decreased the severity of lung structural damage, as assessed by modified Ashcroft scores of fibrosis. E SQL treatment resulted in a moderate, but non-significant decrease in lung fibrosis. Fibrosis scores were quantified by evaluating the Masson’s Trichrome (MT)-stained lung sections are shown. F Representative images of hematoxylin and eosin and Masson’s trichrome staining for fibrosis. Each dot in the bar graphs represents one mouse. ns, non-significant, *p<0.05; *** p<0.001 Soquelitinib reduces Th2 activation and fibrosis-associated mRNA in bleomycin-induced lung fibrosis mice Gene expression in the injured lung was assessed by qPCR using the caval lobe. As shown in Figs. 2, the key transcription factor regulating Th2 cytokine expression, GATA-3, was significantly reduced by 28.1% with the 30 mg/kg dose of SQL (median score [IQR]: 0.62 [0.53–0.83] vs. 0.48 [0.43–0.55]; p = 0.034). In addition, MMP2 (matrix metalloproteinase 2), a gene associated with fibrosis, was reduced by 30.3% with the 30 mg/kg dose of SQL (1.75 [1.48–2.00] vs. 1.35 [1.24–1.69]; p = 0.022). Furthermore, the expression of TGFβ1 (transforming growth factor beta-1), another fibrosis-related mRNAwas reduced by 51.1% with the 30 mg/kg dose of SQL, though this result did not reach statistical significance. Fig. 2Soquelitinib (SQL) reduced Th2 activation and mRNA associated with fibrosis in bleomycin-lung fibrosis induced mice. A Expression of the Th2 lineage defining transcription factor GATA3 in lung tissues as determined by quantitative RT-PCR. CD4 was used for normalization to account for infiltrating CD4 T cell numbers. B and C The expression levels of two fibrosis-associated genes, MMP2 and TGF-ꞵ1, were measured by quantitative RT-PCR in lung tissues. Fold changes in these genes are shown relative to PBS control (B and C). Each dot in the bar graph represents one mouse. ns, non-significant, *p<0.05 Soquelitinib (SQL) reduced Th2 activation and mRNA associated with fibrosis in bleomycin-lung fibrosis induced mice. A Expression of the Th2 lineage defining transcription factor GATA3 in lung tissues as determined by quantitative RT-PCR. CD4 was used for normalization to account for infiltrating CD4 T cell numbers. B and C The expression levels of two fibrosis-associated genes, MMP2 and TGF-ꞵ1, were measured by quantitative RT-PCR in lung tissues. Fold changes in these genes are shown relative to PBS control (B and C). Each dot in the bar graph represents one mouse. ns, non-significant, *p<0.05 Soquelitinib improves clinical scores in Fra-2 mice The effects of SQL were evaluated in transgenic Fra-2 mice that overexpress the transcription factor, Fra-2 (FosL2, an AP1 transcription factor). This mutation results in widespread inflammation, vasculopathy, ILD, and PAH, with vascular injury preceding fibrosis, similar to SSc. The model and assessment techniques have been previously described [23, 24]. In the results, Fra-2 mice will be referred to as simply “Fra-2 mice”. Starting at 11 weeks of age (before the onset of clinical disease), mice were divided into four treatment groups: wild type controls (n = 6), Fra-2 mice receiving regular chow (n = 15), Fra-2 mice receiving low dose SQL-formulated chow (n = 14), and Fra-2 mice receiving the intermediate dose SQL-formulated chow (n = 12). Treatment continued for 7 weeks. As the treatment progresses, Fra-2 mice typically lose weight. As shown in Fig. 3A, Fra-2 mice receiving the intermediate dose of SQL maintained a weight comparable to the control group, unlike Fra-2 mice in the control group or those receiving the lower dose of SQL chow. Fig. 3Soquelitinib (SQL) reduced disease in the Fra-2 model. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A Wild-type mice and mice treated with the intermediate dose of SQL exhibited better weight gain compared to those treated with the lower dose of SQL or the vehicle treated group. B Kaplan-Meier survival curve showing a slight benefit for mice treated with the intermediate SQL dose. The survival curves of the two SQL-treated groups overlap, making it difficult to visually separate them. C SQL treatment improved the clinical score compared to vehicle-treated controls. D The improvement in clinical score for high-dose-treated mice, as determined by the area under the curve (AUC), was significant. ns, non-significant,*** p<0.001. Soquelitinib (SQL) reduced disease in the Fra-2 model. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A Wild-type mice and mice treated with the intermediate dose of SQL exhibited better weight gain compared to those treated with the lower dose of SQL or the vehicle treated group. B Kaplan-Meier survival curve showing a slight benefit for mice treated with the intermediate SQL dose. The survival curves of the two SQL-treated groups overlap, making it difficult to visually separate them. C SQL treatment improved the clinical score compared to vehicle-treated controls. D The improvement in clinical score for high-dose-treated mice, as determined by the area under the curve (AUC), was significant. ns, non-significant,*** p<0.001. In terms of survival, no wild-type control mice died. However, there were 4 deaths in the Fra-2 group on regular chow, 3 deaths in the Fra-2 group on low dose SQL chow, and 2 deaths in the Fra-2 group on intermediate dose of SQL chow (see Kaplan-Meier curve, Fig. 3B). Disease severity was assessed using a ten-point scale, as previously reported [23, 24]. This scale included clinical signs such as blepharitis, alopecia, skin lesions, abnormal fur texture, hepatomegaly, hunched posture, and impaired mobility. Weight loss was also measured: 0 to 5% weight loss received 1 point, 5 to 10% loss received 2 points, and 10 to 15% loss received 3 points. As shown in Fig. 3C, the Fra-2 group treated with the intermediate dose of SQL showed significant improvement in clinical score compared to the untreated or low-dose SQL groups. The onset of improvement was statistically significant as early as two weeks began. When comparing the area under the curve for clinical scores (Fig. 3D), the group receiving the intermediate dose of SQL chow showed a 71.5% improvement compared to the untreated Fra-2 group (median score [IQR]: 14 [7.5–19.5] vs. 4.2 [2–6.3]; p = 0.0001). Soquelitinib attenuates inflammatory cell infiltration and alleviates interstitial lung disease in Fra-2 mice Lung specimens from Fra-2 control mice exhibited typical features of fibrosing alveolitis. Treatment with SQL resulted in a significant 31.8% reduction of the Aschcroft score at the intermediate dose compared to Fra-2 control mice (median score [IQR]: 5 [4–6] vs. 3 [2–4]; p = 0.015) (Fig. 4). The low-dose SQL group also showed a trend toward reduced lung injury, though this difference did not reach statistical significance. Representative trichrome staining for fibrosis is shown in Fig. 4B. Fig. 4Soquelitinib (SQL) alleviated inflammatory cell infiltration in the lung of Fra-2 mice. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A Left: Representative lung sections stained by hematoxylin and eosin. (magnification: top × 8; bottom x100; scale bars: top 1000µm, bottom 50µm). Right: Histological lung fibrosis score (Ashcroft scale) showing improvement with the intermediate dose of SQL. B Representative lung sections stained with Masson’s Trichrome highlighting collagen deposition (magnification ×100). C-D-E Left: Representative IHC staining of T cells (CD3 +) (C), macrophages (CD68 +) (D), and neutrophils (Ly6G +) (E) on 4-μm-thick lung sections, counterstained with hematoxylin (magnification: left × 10; right × 100; scale bars: left 1000µm, right 50µm). Right: Quantification of CD3, CD68, and LY6G cell counts. ns, non-significant, *p<0.05; ** p<0.01; *** p<0.001 Soquelitinib (SQL) alleviated inflammatory cell infiltration in the lung of Fra-2 mice. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A Left: Representative lung sections stained by hematoxylin and eosin. (magnification: top × 8; bottom x100; scale bars: top 1000µm, bottom 50µm). Right: Histological lung fibrosis score (Ashcroft scale) showing improvement with the intermediate dose of SQL. B Representative lung sections stained with Masson’s Trichrome highlighting collagen deposition (magnification ×100). C-D-E Left: Representative IHC staining of T cells (CD3 +) (C), macrophages (CD68 +) (D), and neutrophils (Ly6G +) (E) on 4-μm-thick lung sections, counterstained with hematoxylin (magnification: left × 10; right × 100; scale bars: left 1000µm, right 50µm). Right: Quantification of CD3, CD68, and LY6G cell counts. ns, non-significant, *p<0.05; ** p<0.01; *** p<0.001 Regarding inflammatory infiltrates, T cell (CD3+) counts were significantly reduced by 58.7% (88.0 [82–103] vs. 213.0 [159–266]; p < 0.0001) in the low SQL group and by 62.4% (80.0 [54–103] vs. 213.0 [159–266]; p < 0.0001) in the intermediate-dose SQL group, compared to Fra-2 controls receiving control chow (Fig. 4C). SQL treatment also led to a significant reduction in macrophage (CD68+), with reductions of 47.6% for the low and intermediate doses, respectively (38.0 [27–53] vs. 72.5 [55–90]; p = 0.003, and 38.0 [25–55] vs. 72.5 [55–90]; p = 0.002, respectively) (Fig. 4D). Furthermore, neutrophil (Ly6G+) counts were reduced by 52.4% in the low-dose group (42.5 [30–45] vs. 12 [5–15]; p = 0.0043), and by 48.4% in the intermediate-dose group (42.5 [30–45] vs. 13 [5–30]; p = 0.012) compared to the group receiving control chow (Fig. 4E). Finally, we evaluated STAT3 expression in SQL-treated Fra-2 mice and observed that both doses significantly reduced the expression of this transcription factor compared to untreated Fra-2 controls (Supplementary Fig. 1). Assessment of the effect of soquelitinib on multiple outcome measures related to lung fibrosis in Fra-2 mice The hydroxyproline content in lung specimens from Fra-2 mice showed an increase compared to wild-type mice, but no significant difference was observed between Fra-2 mice treated with SQL as compared to the control mice (Fig. 5A). Quantitative analysis of fibrillar collagen deposits, measured by second-harmonic generation (SHG) microscopy, revealed a trend toward improvement in SQL-treated mice, although this did not reach statistical significance (Fig. 5B). Fig. 5Evaluation of Soquelitinib (SQL) effects on various lung fibrosis outcome measures, including micro-CT images of the lungs in Fra-2 mice. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A Assessement of collagen content in lung fragments using the hydroxyproline assay. B Scoring of fibrillar collagen in lung sections assessed by second harmonic generation (SHG) imaging. C Representative micro-CT images of the lungs. D Lung density at microcomputed tomography (micro-CT). E Percentage of functional residual capacity (FRC) as measured by micro-CT. ns, non-significant Evaluation of Soquelitinib (SQL) effects on various lung fibrosis outcome measures, including micro-CT images of the lungs in Fra-2 mice. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A Assessement of collagen content in lung fragments using the hydroxyproline assay. B Scoring of fibrillar collagen in lung sections assessed by second harmonic generation (SHG) imaging. C Representative micro-CT images of the lungs. D Lung density at microcomputed tomography (micro-CT). E Percentage of functional residual capacity (FRC) as measured by micro-CT. ns, non-significant Chest tomography was next used to quantitatively assess lung parenchymal changes and respiratory capacities (Fig. 5 C). Both lung density and functional residual capacity (FRC) were lower in Fra-2 mice treated with SQL compared to the controls receiving control chow; however, these differences were not statistically significant. Specifically, the mean lung density was − 483.7 HU (Hounsfield Units) in the intermediate-dose SQL group versus − 442.5 HU in the control group (median score [IQR]: − 421.74 [–502.83 to − 351.14] vs. − 502.49 [–523.90 to − 466.22]; p = 0.306), representing a 9.32% reduction. No significant differences were observed between the low-dose SQL group and the control group (Fig. 5D). Regarding FRC, the mean value was 76.4% in the intermediate-dose SQL group compared to 60.7% in the control group (68 [50–81] vs. 80 [74–86]; p = 0.172), reflecting a 25.9% increase. Again, no significant differences were detected between the low-dose SQL group and the control group (Fig. 5E). Soquelitinib reversed pulmonary hypertension in Fra-2 mice Cardiovascular changes in Fra-2 mice were assessed, and we found that treatment with SQL significantly reduced right ventricular pressure, a key indicator of PAH. Specifically, SQL treatment led to a 14.3% reduction in right ventricular systolic pressure (RVSP) in the intermediate dose SQL group compared to control mice (median score [IQR]: 26.73 [25.10–28.72] vs. 22.86 [19.06–24.73]; p = 0.004) (Fig. 6 A). In addition, although a non-significant 10.3% improvement in the Fulton index (right ventricular weight relative to the combined weight of the left ventricle and interventricular septum) was observed in Fra-2 mice treated with the intermediate dose of SQL (0.34 [0.30–0.37] vs. 0.31 [0.30–0.34]; p = 0.088) (Fig. 6B), there was no significant changes in pulmonary vascular remodeling. Immunostaining for alpha-smooth muscle actin showed a non-significant reduction in the percentage medial wall thickness, with reductions of 18.6% and 22.4% in the low- and intermediate-dose SQL-treated groups, respectively, compared to Fra-2 control mice (Fig. 6C and D). Representative images of hematoxylin and eosin staining and of a smooth muscle actin (αSMA) are shown in Fig. 6E. Fig. 6Soquelitinib (SQL) reversed pulmonary hypertension in Fra-2 mice. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A SQL treatment at the intermediate dose significantly lowered right ventricular systolic pressure (RVSP). B There was a trend toward improvement in the Fulton index (right ventricular weight divided by the combined weight of the left ventricle and the intraventricular septum) in Fra-2 mice treated with SQL at the intermediate dose (p=0.088). C Vessel wall evaluation showed increased in wall thickness in the Fra-2 control mice, which was reduced by SQL treatment (non-significant). D Percentage of distal artery muscularization. E Top: representative images of hematoxylin and eosin staining. Bottom: representative images of a smooth muscle actin (αSMA). ns, non-significant,** p<0.01 Soquelitinib (SQL) reversed pulmonary hypertension in Fra-2 mice. WT refers to wild-type controls, and “control” indicates Fra-2 mice treated with vehicle. A SQL treatment at the intermediate dose significantly lowered right ventricular systolic pressure (RVSP). B There was a trend toward improvement in the Fulton index (right ventricular weight divided by the combined weight of the left ventricle and the intraventricular septum) in Fra-2 mice treated with SQL at the intermediate dose (p=0.088). C Vessel wall evaluation showed increased in wall thickness in the Fra-2 control mice, which was reduced by SQL treatment (non-significant). D Percentage of distal artery muscularization. E Top: representative images of hematoxylin and eosin staining. Bottom: representative images of a smooth muscle actin (αSMA). ns, non-significant,** p<0.01 Soquelitinib reduced Th2 and Th17 activation in Fra-2 mice To evaluate the impact of SQL on T cell activation, we performed flow cytometry to assess T cell subsets in the spleens of Fra-2 mice (Supplementary Fig. 2). In mice treated with SQL GATA-3 expression in Th2 cells was lower compared to untreated Fra-2 mice. In contrast, the expression of RORγt a key transcription factor for Th17 cell differentiation, was significantly reduced in the low and intermediate-dose SQL groups compared to untreated Fra-2 mice. Fra-2 mice that were untreated displayed lower levels of Th1 cells expressing the transcription factor Tbet, and Treg cells expressing Foxp3 when compared to wild-type controls. However, treatment with SQL did not result in statistically significant changes in the expression of Tbet or Foxp3. In addition, no significant effects were observed on other markers or cell surface markers, including total CD4, total CD8, PD1 (which trended lower), CD69, and effector memory or central memory cells in either CD4 or CD8 T cell subsets. We performed flow cytometry to assess T cell subsets in the lungs of Fra-2 mice (Supplementary Fig. 3). SQL-treated mice showed reduced CD3 + and CD4 + and PD-1 positive T cell populations compared to untreated Fra-2 mice. Finally, we measured serum pro-inflammatory cytokine levels in Fra-2 mice (Supplementary Fig. 4) and found that SQL treatment let to a reduction in circulating IL-6 levels, with a 54.5% decrease in the intermediate-dose SQL group (205.07 [140.49–291.78] vs. 116.23 [97.47–151.01]; p = 0.01). There was also a non-significant trend towards decreased circulating IL-17 levels, with a 31.8% reduction. No significant differences were observed in the levels of circulating IL-2, IL-1, IL-4, or IL-10. Discussion Our study provides the first evidence that ITK inhibition with SQL attenuates lung damage severity in two complementary mouse models of SSc. Specifically, we observed that SQL substantially improved lung inflammation parameters and reduced structural damage in the bleomycin-induced lung fibrosis model. In the Fra-2 transgenic model, which closely mimics fibrosing alveolitis and PAH—two key features of human SSc—SQL treatment improved clinical scores, reduced inflammation, alleviated vascular remodeling, and partially reversed PAH. Additionally, SQL-treated mice exhibited lower lung weights and a slight reduction in mortality, further supporting its protective effects. These findings are of particular significance because fibrosing alveolitis remains a major cause of death in SSc patients, and there are currently limited effective therapies for this devastating condition [25]. Furthermore, in the Fra-2 model, SQL treatment resulted in reduced vascular remodeling and PAH, highlighting its potential to address multiple facets of SSc pathology. Given the close relationship between endothelial dysfunction and vessel inflammation in SSc-PAH pathogenesis, targeting these pathways could offer a promising therapeutic strategy to prevent or halt disease progression. The benefits conferred by SQL treatment in these two experimental models may be its targeting Th2 and Th17 and therefore inhibiting proinflammatory and profibrotic pathways. In the bleomycin-induced lung fibrosis model, SQL treatment reduced the expression of GATA-3, a key Th2 transcription factor. In the Fra-2 model, we observed a decreased expression in both STAT3 and RORγt, the major Th17 transcription factor. These findings were corroborated by reduced circulating levels IL-6 and IL-17 in the Fra-2 model, as well as a decrease in CD3+, CD68+, and Ly6G + immune cell infiltration into lesional lungs. This suggests that SQL exerts anti-inflammatory effects, mitigating lung damage and alveolitis. We acknowledge that Th1 polarization plays an important role in SSc pathogenesis, particularly regarding pulmonary vascular disease and PAH [26]. However, recent evidence has demonstrated significant contributions of Th2 and Th17 responses to SSc pulmonary pathology [27, 28]. Given SQL’s selective antagonizing effects on Th2 and Th17 pathways with minimal impact on Th1 responses, we believe that the beneficial effects observed on pulmonary vascular remodeling in the Fra-2 model may be driven primarily by modulation of these alternative inflammatory pathways. This suggests that targeting Th2 and Th17 responses may provide complementary therapeutic benefits to existing treatments that focus on Th1-mediated pathology. Despite these anti-inflammatory effects, the anti-fibrotic impact of SQL was more modest. This discrepancy may stem from the inherent limitations of the models, which primarily reflect acute or subacute inflammation rather than fully established fibrosis. For the bleomycin model, lung mRNA expression analysis is shown in Fig. 2, demonstrating how SQL treatment affected key fibrosis-related genes. Unfortunately, we could not perform reliable mRNA expression analysis in the Fra-2 model due to poor RNA quality during extraction from lung tissue samples. It is also possible that longer treatment durations or higher doses of SQL could yield more pronounced anti-fibrotic effects. Another explanation could be that SQL primarily targets inflammatory pathways without directly interfering with the key fibrotic drivers, such as TGF-β1 or collagen deposition. It is important to note, as a limitation of this study, that the bleomycin model was employed as an exploratory approach to assess the preliminary effects of SQL on alveolitis. This model was conducted by an external research partner, which limited our ability to perform replicate studies with this particular model. The stimulatory effects observed in the bleomycin model were further characterized in-house using the Fra-2 transgenic model, which we believe represents a more relevant and accurate model of SSc pathogenesis. Regarding mortality outcomes, we observed 3 deaths in the Fra-2 group receiving low-dose SQL and 2 deaths in the Fra-2 group receiving intermediate-dose SQL. However, the small number of mortality events does not allow one to draw definitive conclusions about potential dose-dependent effects of SQL on survival. Future studies with larger sample sizes will be necessary to validate these preliminary findings. When comparing the effects of SQL to those of other therapeutic interventions in the Fra-2 model, we found comparable outcomes in terms of lung inflammation and T cell infiltration. For instance, arsenic trioxide (ATO) [29] reduced Ashcroft scores by 33% and T cell counts by 57%, whereas SQL achieved reductions of 31.8% and 41.5%, respectively. ATO had a stronger effect on vascular remodeling, with greater reductions in RVSP and medial wall thickness. Other immunomodulatory treatments- such as abatacept [30] OX40-ligand blockade [31], and acazicolcept-also showed beneficial effects, though they target different immune pathways. While direct comparisons between studies should be interpreted with caution due to experimental variability, these findings suggest that SQL performs within a comparable efficacy range. Despite substantial progress in understanding the pathogenic mechanisms of SSc and the increasing number of therapeutic agents undergoing clinical trials, effective therapies—especially for cardiopulmonary complications—remain limited. Currently, only a handful of targeted therapies, such as nintedanib, tocilizumab, and rituximab, have been approved by some agencies for SSc treatment [32]. It is essential to emphasize the positive effects observed in lung inflammation across the two complementary models used in this study. In the bleomycin-lung fibrosis model, mice exhibit acute inflammation, characterized by patchy parenchymal inflammation, oxidative stress, and the subsequent activation and differentiation of fibroblasts into myofibroblasts. This is accompanied by upregulation of TGF-β1-dependent and TNF-α-induced NF-κB pathways, as well as an overexpression of collagen [33, 34]. In contrast, Fra-2 transgenic mice present with capillary changes, pulmonary fibrosis, and PAH, making them a unique model for SSc. These mice overexpress the AP-1 transcription factor Fra-2 which drives the development of perivascular and peribronchial inflammation, severe fibrosis, and vascular remodeling. This remodeling is characterized by collagen deposition in vessel walls and increased muscularization, ultimately leading to PAH [35]. The therapeutic effects of SQL observed across these models suggest that its therapeutic potential extends beyond targeting a single pathogenic pathway. In the bleomycin model, SQL may primarily act by mitigating inflammatory cascades and oxidative stress. However, experiments in the bleomycin model were conducted at day 21 post-instillation, a time point beyond the early inflammatory phase of this model. Therefore, conclusions regarding early anti-inflammatory effects of SQL in this model cannot be drawn. In the Fra-2 model, SQL appears to influence a combination of inflammatory, fibrotic, and vascular components, potentially reducing perivascular inflammation and vascular remodeling. These findings underscore the therapeutic promise of SQL in addressing multiple aspects of SSc-related lung pathology. Consequently, further investigation into the specific mechanisms of action in both inflammatory and vascular-driven fibrosis is warranted. ITK inhibition has previously been tested in other fibro-inflammatory conditions, such as chronic graft-versus-host disease (cGVHD), which is characterized by the activation alloreactive donor B and T cells, leading to widespread fibrosis. In a murine model of sclerodermatous cGVHD, ITK inhibition produced pronounced effects in reducing dermal thickness and fibrosis, with a significant reduction in both interferon-gamma and IL-4 [36]. These findings further support the potential of ITK inhibition as a therapeutic strategy for fibrosis-related diseases, including SSc. A major advantage of SQL is its highly selectivity as an ITK inhibitor. At lower doses, SQL, preferentially preserves Th1 pathways [37], which may help reduce the risk of generalized immunosuppression and associated infectious complications. This selectivity is particularly important for SSc patients, who are at an increased risk of infections due to multiorgan involvement, comorbidities, and the need for multiple lines of immunosuppressive treatment. Currently, SQL is being investigated in several ongoing clinical trials for other conditions, including relapsed/refractory peripheral T-cell lymphoma (NCT06561048), moderate to severe atopic dermatitis (NCT06345404), and autoimmune lymphoproliferative syndrome (NCT06730126). The results from these studies will provide valuable insights into the efficacy and tolerability of SQL across different disease settings, and may ultimately inform future clinical trials in SSc, paving the way for the development of a novel therapeutic option for this challenging disease. In conclusion, our study provides compelling evidence that ITK inhibition with SQL results in reduced Th2 and Th17 activation, yielding therapeutic benefits in mouse models of SSc-related lung damage. Given the pivotal role of T cell activation in the early stages of SSc, targeting T cell signaling may represent a promising strategy for treating this complex disease. SQL offers a novel approach for managing lung involvement in SSc, and its effects warrant further exploration in clinical trials. Future studies should compare the efficacy of SQL with current immunomodulatory treatments, as this could help establish its place in the therapeutic landscape for SSc. Materials and methods Animals The bleomycin-induced pulmonary fibrosis model was conducted as a preliminary exploratory study. Female C57BL/6 mice were bred and housed at Charles River Laboratories (USA). The experiments were designed by scientists at Corvus Pharmaceuticals (co-authors on this paper), and the execution of the experiments was performed by Aragen Biosciences (Morgan Hill, California), a third party vendor. Data analysis and interpretation were performed by Corvus Pharmaceuticals scientists. The Fra-2 model was studied in female Fra-2TG mice (B6.Cg-Tg(H2-KFosl2, EGFP)13Wag), housed in a specific, pathogen-free facility (C75-14-02) at the Cochin Institute, Paris, France. Soquelitinib treatment and formulations In the bleomycin-induced lung fibrosis model, soquelitinib was formulated as an oral gavage solution consisting of water, Tween, propylene glycol, and cellulose, and administered at doses of 10 mg/kg or 30 mg/kg. Oral gavage was selected for this acute model due to its suitability for short-duration treatment regimens. Pharmacokinetic analysis revealed that these doses achieved plasma Cmax levels of 600 ng/ml and 3500 ng/ml, respectively (median values, n = 5 animals per group). Cmax measurements were prioritized because SQL is a covalent inhibitor that irreversibly binds to its target, making peak plasma concentrations the most relevant pharmacokinetic parameter. Cmax values were determined using liquid chromatography-mass spectrometry (LC-MS) analysis of plasma samples, with calculations based on average daily chow consumption per mouse over a 21-day period (n = 5 mice per group). Previous studies have demonstrated that SQL achieves target engagement and therapeutic efficacy at these dose levels across multiple preclinical mouse models [21, 38]. Detailed pharmacokinetic data are provided in supplementary Fig. 6. For the Fra-2 transgenic model, a mouse chow formulation of SQL was developed to support chronic dosing regimens. Mice continuously ingested chow containing SQL containing SQL during the dosing period. The chow formulations included 1.2 g SQL/kg chow (low dose) and 2.4 g SQL/kg chow (intermediate dose). These formulations resulted in plasma Cmax levels of 2000 ng/ml, and 3800 ng/ml, respectively (median, 5 animals/group). Bleomycin-induced lung fibrosis model Thirty-four eight-week-old female C57BL6 mice were randomly divided into 4 groups (Group A-D, Fig. 1 A). On day 0, 29 animals were administered bleomycin (1.5U/kg, Hospira) via the oropharyngeal route, while five animals were administered normal saline as Group 1. On day 6, bleomycin-treated animals were randomly allocated into Groups B-D, ensuring equal distribution of mean body weight across the groups. Starting on day 7 post-bleomycin administration, animals were treated once daily (QD) via oral gavage with either vehicle control or one of two doses of Soquelitinib (SQL) (10 mg/kg or 30 mg/kg) in solution. Treatment continued until the study termination on day 21, as outlined in Fig. 1A. On day 21, all surviving animals were harvested 1 to 3 h post-final dosing. Following euthanasia, lungs (excluding the post caval lobe) were weighed and processed for histopathology. BALF was collected and centrifuged to determine differential cell counts, which were assessed via cytospin of cells recovered from individual mice. The post-caval lobes were frozen immediately in liquid nitrogen for subsequent RT-PCR mRNA quantification. Fra-2 transgenic mice Fra-2 transgenic mice, which express the Fra2 gene under the control of the ubiquitous major histocompatibility complex class I antigen H-2Kb promoter, develop systemic fibrosis, microangiopathy, and PAH [39]. Treatment began at 11 weeks of age, coinciding with the onset of clinical disease, and continued until the mice reached 18 weeks of age. The mice were divided into four groups: wild-type controls (n = 6), Fra-2 mice receiving regular chow (n = 15), Fra-2 mice receiving daily chow that included 1.2 g/kg of SQL (low dose) (n = 14), and Fra-2 mice receiving daily chow that contained 2.4 g/kg of SQL (intermediate dose) (n = 12). Clinical follow up of Fra-2 mice Fra-2 mice exibit a disease phenotype that requires diligent clinical monitoring on a daily basis. Both experimental groups were weighed and individually assessed for physical appearance and general behavior on a weekly basis. A clinical score, ranging from 0 to 10, was assigned to each mouse based on the extent of body weight loss (scored from 0 to 3, with 0 indicating no weight loss, 1 indicating weight loss of less than 10%, 2 indicating weight loss between 10% and 20%, and 3 indicating weight loss of over 20%) as well as the presence of specific symptoms such as blepharitis, alopecia, skin sclerosis, hepatomegaly, ruffled fur, hunched posture, and lethargy. At the time of sacrifice, all wild type control mice (n = 6) were alive. In the Fra-2 groups, 11 mice remained in the regular chow group, 11 in the low-dose SQL group, and 10 in the intermediate-dose SQL group, resulting in a total of 38 mice available for analysis. Histopathologic assessment of fibrosing alveolitis and fibrotic changes The left lung of sacrificed Fra-2 mice was excised and embedded in paraffin for histological analysis. Lung sections, 4-µm thick, were stained with hematoxylin eosin. The severity of fibrosing alveolitis was evaluated semi-quantitatively using the scoring method established by Ashcroft et al. [22]. Two blinded examiners assessed the entire left upper lobe, grading fibrosis on a scale of 0 to 8. The grading criteria were as follows: grade 0 = normal lung; grade 1 = minimal fibrous thickening of alveolar walls; grade 3 = moderate thickening of walls without obvious damage; grade 5 = increased fibrosis with definite damage and formation of fibrous bands; grade 7 = severe distortion of structure and large fibrous areas; and grade 8 = total fibrous obliteration. Intermediate grades (Grades 2, 4 and 6) represented stages between these key criteria. The severity of fibrotic/reparative changes (“Fibrosis score”) was evaluated semi-quantitatively using the scoring method established by Cherniack et al. [40] All images were captured using a Lamina Multilabel Slide Scanner (Perkin Elmer, Waltham, MA) and analyzed using CaseViewer software (version 2.4). Collagen measurements in Fra-2 transgenic mice Collagen content was quantified using the hydroxyproline assay, as previously described [41]. Lung biopsies (from right lobe for each mouse) were collected, hydrolyzed, and adjusted to pH 7. The hydrolyzed samples were then reacted with chloramine T and p-dimethylaminobenzaldehyde in perchloric acid. The absorbance was measured at 557 nm using a spectrophotometer (Molecular Devices, Sunnyvale, CA) to determine collagen content based on hydroxyproline levels. Assessment of fibrosing alveolitis by chest micro-computed tomography (micro-CT) Fibrosing alveolitis of mice was evaluated using micro-CT 2 days prior to sacrifice, as described previously [42]. CT images were obtained using a Perkin Elmer Quantum FX system (Caliper Life Sciences, GmbH, Mainz, Germany). Mice were placed in a supine position on the CT table and sedated with 3–4% isoflurane anesthesia under 0.5–1.5 L/min for induction by a nose cone. Anesthesia was maintained with 2.5–3.5% isoflurane under 400–800 mL/min during the acquisition. During image acquisition thoracic breathing movements were recorded, detecting the up- and downward movements of the thorax. Images were acquired throughout the spontaneous respiratory cycle. Only images acquired during expiration were analyzed. Images were acquired with the following parameters: 90 kV X-ray source voltage, 160 µA current. Total scanning time was approximately 4.5 min per mouse. Means of lung density of both groups were achieved by evaluation of all CT scans acquired from the apices to the bases of the lungs. Furthermore, the volume of functional lung parenchyma corresponding to functional residual capacity (FRC) was manually drawn, by excluding fibrosis area and vessels. Percentages of FRC on total lung volumes were calculated. The CT expert (FT) was blinded to the background of the mice, to the treatment and to the results of the histological assessment. Hemodynamic measurements and assessment of vessel remodeling Right ventricular systolic pressure (RVSP) and heart rate were measured in unventilated mice under isoflurane anesthesia (1.5–2.5%, 2 L O2/min) using a closed chest technique. A 1.4-F catheter (Millar Instruments Inc., Houston, TX) was introduced into the jugular vein and directed to the right ventricle. After completing the hemodynamic assessments, blood was collected via direct cardiac puncture. After completing the hemodynamic assessments, blood was collected via direct cardiac puncture, and the mice were sacrificed by exsanguination. The heart and lungs were removed, flushed with 5 mL buffered saline at 37 °C, and the left lung was prepared for morphometric analyses. The right lung was quickly harvested, snap-frozen in liquid nitrogen, and stored at − 80 °C. Morphometric analyses were conducted on paraffin-embedded lung sections stained with hematoxylin and eosin and alpha smooth muscle actin (α-SMA). α-SMA was detected by incubating the slides overnight at 4 °C with monoclonal anti-α-SMA antibody (clone 1A4; Dako Glostrup, Denmark) at a dilution of 1:100. A Vectastain ABC kit was used according to the manufacturer’s instructions (Vector Laboratories, Burlingame, CA), and slides were counterstained with hematoxylin (Sigma-Aldrich). The percentage of wall thickness ([2 × medial wall thickness/external diameter] × 100) and of muscularized vessels was determined as described previously [43]. Morphometric analyses were performed by two examiners (MO and CG), who were blinded to the genotype and treatment conditions. Immunohistochemistry Cell infiltration was identified in paraffin-embedded sections. After antigen retrieval, blocking and tissue permeabilization with PBS + 0.25% Triton X-100, lung sections were incubated overnight at 4 °C with the following primary antibodies diluted in PBS + 0.5% BSA: rabbit anti-CD3 (Abcam, clone, dilution 1/100), rabbit anti-CD68 (Abcam, dilution 1/100), rat anti-Ly6G (BD Biosciences, Clone 1A8, dilution 1/500), rabbit anti-STAT3 (phospho Y705) antibody (Abcam, dilution 1/100). Polyclonal goat anti-rabbit (1/200) or goat anti-rat antibodies (Invitrogen, dilution 1/500) labeled with horseradish peroxidase (HRP) were used as secondary antibodies for 1 h at room temperature. Immunoreaction products were revealed using diaminobenzidine (DAB) solution (Liquid DAB + Substrate Chromogen System, Dako, Denmark). The Lamina multilabel Slide Scanner was used to analyze the immunostaining, slide staining analysis was performed with CaseViewer (version 2.4) or QuPath (version 0.6.0) software. Cell isolation for flow cytometry staining Spleen were homogenized and passed through a nylon cell strainer (BD falcon) in PBS supplemented with 10% FCS. The cells were washed twice, resuspended in 5% PBS, and dispended into 96-well conic-bottom microtiter plates at the concentration of 6 × 10 6 cells per well (Greiner Bioscience) for flow cytometry staining. The lung biopsies were incubated in PBS 10% FBS + Collagenase II (1 mg/mL), and DNase I (0.1 mg/mL), (both from StemCell Technologies) for 1 h at 37 °C. The digested tissues were filtered through a 70-µm strainer (BD Biosciences). A Percoll (Sigma-Aldrich, St. Louis, MO) density gradient was generated by resuspending cells in a 40% Percoll solution and adding an 80% Percoll solution below the 40% solution. The cells were collected in the interface, washed, and resuspended in 2% FCS in PBS for flow cytometry cell surface staining. Fc receptors were blocked with the TruStain FcXTM (anti-mouse CD16/32) Antibody (Clone 93, Biolegend) for 5 min on ice. Cells were stained with the following antibodies against CD3 (17A2), CD 4 (RM4-5), CD8 (53 − 6.7), CD69 (H1.2F3), PD-1 (29 F.1A12), TCRβ (H57-597), CD25 (PC61), CD44 (IM7), CD62L (MEL-14), CCR4 (2G12) and CCR6 (29-2L17) from BioLegend, CXCR3 (REA724) from Miltenyi Biotec. The Foxp3/Transcription Factor Staining kit (eBioscience) was used for Foxp3 (FJK-16s, Invitrogen), GATA3 (L50-823, BDBiosciences), RORgt (REA278, Miltenyi Biotec) and Tbet (REA102,Miltenyi Biotec) intracellular staining. Data acquisition was performed on a BD LSR Fortessa Cytometer, and data were analyzed with FlowJo Software (version 10.7.2).The flow cytometry gating strategy is provided in Supplementary Fig. 5. Statistical analyses Data are expressed as the median [IQR]. Mann-Whitney tests were used to assess the statistical significance of differences between two groups. Differences were considered significant for p-values < 0.05. Analyses were performed using PRISM software (version 8.3.0) (GraphPad, la Jolla). Supplementary Information Supplementary Material 1. Supplementary Material 1.